Related Experiment Video
Updated: Mar 1, 2026
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
Emerging growth factor receptor antagonists for the treatment of advanced melanoma
Sarah E Fenton1, Jeffrey A Sosman2, Sunandana Chandra2
1a Internal Medicine Department , Chicago , IL , USA.
Introduction:
Therapy for metastatic melanoma has undergone a rapid transformation over the past 5-10 years. Advances in immunotherapy with checkpoint inhibitors, including both anti-CTLA-4 and anti-PD-1/PD-L1, have led to durable responses in up to 50% of patients. As our understanding of the processes driving the transformation of melanocytes has improved, progress in targeted therapies has also continued. Areas covered: Angiogenesis and the tumor's dependence on an expanded vascular supply has been a target for novel therapies since the 1970's, as this tissue is derived from endothelial cells that are genetically stable in adults. A phase II trial studying combined therapy with bevacizumab (an inhibitor of angiogenesis) and ipilimumab found promising results. Other agents such as sorafenib have not been as successful, failing to extend progression free or overall survival in clinical trials. In this paper other targeted growth factor inhibitors will also be discussed. Expert opinion: Ultimately, melanoma may not be vulnerable solely to chemotherapy or targeted therapy, but may be efficaciously treated with immunotherapy due to its high mutational rate resulting in the expression of numerous neo-antigens. Therapies with combinations of agents including growth factor receptor and either other targeted therapies or immunotherapy may be a promising complimentary approach.
Insights
Metastatic melanoma treatment has advanced with immunotherapy, showing durable responses in 50% of patients. Combination therapies targeting angiogenesis and growth factors show promise for improved outcomes.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Metastatic melanoma therapy has rapidly evolved in the last decade.
- Immunotherapy, including checkpoint inhibitors (anti-CTLA-4, anti-PD-1/PD-L1), has yielded durable responses in up to 50% of patients.
- Targeted therapies have also progressed with improved understanding of melanocyte transformation.
Purpose of the Study:
- To review recent advances in metastatic melanoma treatment.
- To discuss the role of immunotherapy and targeted therapies.
- To explore the potential of combination treatment strategies.
Main Methods:
- Review of immunotherapy agents like anti-CTLA-4 and anti-PD-1/PD-L1.
- Discussion of targeted therapies, including angiogenesis inhibitors (e.g., bevacizumab).
- Analysis of clinical trial outcomes for agents like sorafenib and combined therapies.
Main Results:
- Immunotherapy provides durable responses in a significant portion of melanoma patients.
- Combined therapy with bevacizumab and ipilimumab showed promising results in a Phase II trial.
- Some targeted agents like sorafenib have not demonstrated improved survival outcomes.
Conclusions:
- Metastatic melanoma may be effectively treated with immunotherapy due to its high mutational rate and neo-antigen expression.
- Combination therapies involving growth factor inhibitors and immunotherapy represent a promising approach.
- Future treatment strategies may involve combining different therapeutic modalities for enhanced efficacy.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...